Arcturus Therapeutics Holdings annual revenue
2018
2019
2020
2021
2022
2023
2024
2025
Arcturus Therapeutics Holdings Revenue Growth & History (ARCT)
Arcturus Therapeutics Holdings reported $82.0M in revenue for fiscal 2025, a decrease of 46.14% from the previous fiscal year.
View full Arcturus Therapeutics Holdings company overviewArcturus Therapeutics Holdings annual revenue and growth
| Fiscal year | Period ended | Revenue | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $82.0M | −$70.3M | −46.14% |
| 2024 | 2024-12-31 | $152.3M | −$14.5M | −8.69% |
| 2023 | 2023-12-31 | $166.8M | −$39.2M | −19.03% |
| 2022 | 2022-12-31 | $206.0M | $193.6M | +1566.79% |
| 2021 | 2021-12-31 | $12.4M | $2.8M | +29.56% |
| 2020 | 2020-12-31 | $9.5M | −$11.3M | −54.12% |
| 2019 | 2019-12-31 | $20.8M | $5.0M | +31.97% |
| 2018 | 2018-12-31 | $15.8M | — | — |
Arcturus Therapeutics Holdings quarterly revenue
Q2.18
Q3.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Revenue | Change | YoY growth |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $3.0M | −$25.3M | −89.54% |
| Q1 2026 | 2026-03-31 | $2.1M | −$27.3M | −92.99% |
| Q4 2025 | 2025-12-31 | $7.2M | −$15.6M | −68.39% |
| Q3 2025 | 2025-09-30 | $17.2M | −$24.5M | −58.84% |
| Q2 2025 | 2025-06-30 | $28.3M | −$21.6M | −43.24% |
| Q1 2025 | 2025-03-31 | $29.4M | −$8.6M | −22.70% |
| Q4 2024 | 2024-12-31 | $22.8M | −$8.1M | −26.22% |
| Q3 2024 | 2024-09-30 | $41.7M | −$3.5M | −7.68% |
| Q2 2024 | 2024-06-30 | $49.9M | $39.3M | +373.99% |
| Q1 2024 | 2024-03-31 | $38.0M | −$42.3M | −52.65% |
| Q4 2023 | 2023-12-31 | $30.9M | −$129.4M | −80.75% |
| Q3 2023 | 2023-09-30 | $45.1M | $31.8M | +237.65% |
| Q2 2023 | 2023-06-30 | $10.5M | −$16.6M | −61.17% |
| Q1 2023 | 2023-03-31 | $80.3M | $75.0M | +1430.99% |
| Q4 2022 | 2022-12-31 | $160.3M | $154.5M | +2666.53% |
| Q3 2022 | 2022-09-30 | $13.4M | $10.9M | +448.58% |
| Q2 2022 | 2022-06-30 | $27.1M | $25.1M | +1253.97% |
| Q1 2022 | 2022-03-31 | $5.2M | $3.1M | +146.54% |
| Q4 2021 | 2021-12-31 | $5.8M | $3.6M | +158.89% |
| Q3 2021 | 2021-09-30 | $2.4M | $104,000 | +4.46% |
| Q2 2021 | 2021-06-30 | $2.0M | −$321,000 | −13.82% |
| Q1 2021 | 2021-03-31 | $2.1M | −$519,000 | −19.61% |
| Q4 2020 | 2020-12-31 | $2.2M | −$730,000 | −24.60% |
| Q3 2020 | 2020-09-30 | $2.3M | −$985,000 | −29.69% |
| Q2 2020 | 2020-06-30 | $2.3M | −$7.8M | −77.13% |
| Q1 2020 | 2020-03-31 | $2.6M | −$1.7M | −39.17% |
| Q4 2019 | 2019-12-31 | $3.0M | — | — |
| Q3 2019 | 2019-09-30 | $3.3M | −$105,000 | −3.07% |
| Q2 2019 | 2019-06-30 | $10.2M | $7.8M | +325.52% |
| Q1 2019 | 2019-03-31 | $4.3M | — | — |
| Q3 2018 | 2018-09-30 | $3.4M | — | — |
| Q2 2018 | 2018-06-30 | $2.4M | — | — |
Arcturus Therapeutics Holdings revenue growth trends
Over the last five reported fiscal years, revenue grew from $9.5M to $82.0M, a compound annual growth rate of 53.78%. Arcturus Therapeutics Holdings's latest reported quarter, Q2 2026, generated $3.0M in revenue, a decrease of 89.54% year over year.
About the data
What revenue means
Revenue is the top-line amount a company reports from selling goods and services before expenses are deducted. Fiscal periods can differ from calendar years, so each table includes the exact period end date.
Financial data
Standardized company financials
TickerStat standardizes company financial facts for consistent comparison. Derived growth rates use the displayed values and are not guidance or forecasts.
Review Arcturus Therapeutics Holdings source filings ↗